Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21401553 | 0.98 | HCAR2 (0.58) | HCAR2HCAR3GPR84KCNH2 | |
| SCHEMBL28317128 | 0.98 | HCAR2 (0.58) | HCAR2HCAR3GPR84KCNH2 | |
| Bromide SCHEMBL31310739 | 0.96 | HCAR2 (0.57) | HCAR2HCAR3GPR84KCNH2 | |
| SCHEMBL5960663 | 0.96 | HCAR2 (0.57) | HCAR2HCAR3GPR84KCNH2 | |
| SCHEMBL2765959 | 0.94 | HCAR2 (0.56) | HCAR2HCAR3GPR84KCNH2HRH3 | |
| SCHEMBL5689957 | 0.89 | HCAR2 (0.50) | HCAR2HCAR3KCNH2HRH3 | |
| Pyrrole SCHEMBL28216735 | 0.88 | HCAR2 (0.50) | HCAR2HCAR3GPR84KCNH2HRH3 | |
| SCHEMBL11400077 | 0.86 | HCAR2 (0.58) | HCAR2HCAR3GPR84KCNH2 | |
| SCHEMBL11299460 | 0.86 | HCAR2 (0.58) | HCAR2HCAR3GPR84KCNH2 | |
| SCHEMBL11403179 | 0.86 | HCAR2 (0.58) | HCAR2HCAR3GPR84KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | HCAR2 602/4885HCAR3 948/4885GPR84 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.